Dr Cecily Forsyth

Dr Cecily Forsyth

Clinical Haematologist 

Dr Cecily Forsyth graduated in medicine from the University of Sydney, and after completing her training in haematology at Royal Prince Alfred Hospital, she moved to the Central Coast of NSW to set-up practice as a clinical haematologist in 1996. She was appointed to the Central Coast Local Health District as a VMO Haematologist at Wyong Hospital in 1999.  

She provides holistic and comprehensive care to patients with a wide range of haematological disorders. 

She has a passion for myeloproliferative neoplasms 
(MPN) and has contributed to several national 
and international research collaborations in myeloproliferative neoplasms. She is a member of the MPN subcommittee for the ALLG and an advisor to the MPN Alliance Australia.

She has over 45 publications in peer-reviewed journals, many of which are MPN-related. She has an interest in the use of integrative medicine to improve symptoms and quality-of-life for patients living with MPNs.

Her other medical passions include teaching and training of medical students, junior doctors and nursing staff, and improving access to clinical trials for patients living in regional centres.

Current Appointments

Central Coast Local Health District Gosford and Wyong Hospital

Gosford Private Hospital

Tuggerah Lakes Private Hospital

Berkeley Vale Private Hospital

Brisbane Waters Private Hospital

Specialist Qualifications and Affiliations

Bachelor of Medicine and Bachelor of Surgery (Hons)

Fellow of The Royal Australasian College of Physicians

Fellow of The Royal College of Pathologists of Australasia


  1. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. Coates AS, Childs A, Cox K, Forsyth C, Joshua D, McNeil E, Grygiel J.  Annals of Oncology 1992;3:719-722.

  2. Development of a flow cytometric test for the detection of D-positive fetal cells after fetomaternal haemorrhage and a survey or the prevalence in D-Negative women. Nelson M, Popp H, Horky K, Forsyth C, Gibson J.  Immunohematology 1994;10(2):55-59.

  3. Rapid detection of Rh(D) or K positive fetal red cells in chorion villus samples by a flow cytometric technique. Nelson M, Forsyth C, Popp H, Gibson J.  Transfusion Medicine 1994;4(4):297-302.

  4. First trimester antigen typing of fetal red cells using a flow cytometric technique. Forsyth C, Nelson M, Peat B, Boogert A, Gibson J.  The Australian and New Zealand Journal of Obstetrics and Gynaecology. 1995;35:1:97-98.

  5. Severe haemolysis due to anti-D in a D-negative recipient of an orthotopic liver transplant. Forsyth C, Popp H, Kronenberg H, McCaughan G.  1995;35(3):277.

  6. Quantifying the loss of ABO antigenicity in a patient with acute myeloid leukaemia by flow cytometric analysis. Popp H, Nelson M, Forsyth C, Falson M, Kronenberg H.  1995;11(1):5-7.

  7. Transfusion of patients with haemoglobinopathies. Forsyth C, Chisholm J, Popp H.  Topics in Transfusion Medicine. 1995;2(1):9-11.

  8. Kit-positive peripheral blood cells collected after chemotherapy and G-CSF priming. Gibson J, Jamieson S, Forsyth C, Armstrong M, Brown R, Joshua D.  “Autologous Marrow and Blood Transplantation.  Proceedings of the Seventh International Symposium. Edited by Karel A Dicke and Armand Keating, 1994.

  9. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young adults. Adams M, Forsyth C, Jessup W, Robinson J, Celermajer D.  Journal of the American College of Cardiology. 1995;26(4):1054-61.

  10. Hodgkin’s disease: A GP’s guide to diagnosis and management. Forsyth C, Joshua D.  Modern Medicine. 1996;39(6):127-135.

  11. Thalidomide responsive chronic pulmonary graft-versus-host-disease. Forsyth CJ, Cremer PD, Torzillo P, Iland HJ, Young GAR.  Bone Marrow Transplantation. 1996;17:291-293.

  12. Autologous red cell recovery and relapse of multiple myeloma after bone marrow transplantation: Is this a graft-versus-myeloma effect? Forsyth C, Nelson M, Popp H, Snowdon L, Gibson J, Joshua D.  Bone Marrow Transplantation. 1996;17:457-459.

  13. A quick differentiation between iron deficiency and thalassaemia syndrome. Yuen S, Brown R, Forsyth C, Zarkos K.  Australian Journal of Medical Science. 1996;17:106-109.

  14. Rapid quantitation of mixed red cell populations using flow cytometry. Nelson M, Popp H, Forsyth C, Gibson J.  Lab. Haem. 1996;18:207-213.

  15. The management of acute vascular graft thrombosis associated with HIT syndrome: a case report. Wilson M, Forsyth C, McGahan T, White G.  The Australian and New Zealand Journal of Surgery. 1997;67(5):302-3.

  16. Abnormal dicentric chromosome with co-amplification of sequences from chromosomes 11 and 19: a novel rearrangement in a patient with myelodysplastic syndrome transforming to acute myeloid leukemia. Smith A, St.Heaps L, Sharma P, Jarvis A, Forsyth C.  Cancer Genetics and Cytogenetics. 2001;130:29-32.

  17. Collection and transport of samples for laboratory testing in von Willebrand’s disease (VWD): Time for a reappraisal? Favaloro EJ, Nair SC, Forsyth CJ.  Thrombosis and Haemostasis. 2001;86:1589-90.

  18. The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. Giles Best, Nisha Singh, Cecily Forsyth, Stephen P. Mulligan. Br J Haematol. 2010;151(2):185-188.

  19. Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Judith Trotman, Marion Fournier, Thierry Lamy, John Francis Seymour, Anne Sonet, Andrea Janikova,  Ofer Shpilberg, Emmanuel Gyan, Hervé Tilly, Jane Estell, Cecily Forsyth, Didier Decaudin, Bettina Fabiani, Jean Gabarre, Bruno Salles, Eric Van Den Neste,  Danielle Canioni, Etienne Garin, Michael Fulham, Thierry Vander Borght and Gilles Salles. JCO. 2011;35.0736.

  20. Distinguishing types 1 and 2M von Willebrand disease. Favaloro EJ, Forsyth C, Koutts J. International Journal of Laboratory Haematology. 2012;34(1):102-105

  21. The Hsp-90 inhibitor SNX-7081 synergises with and restores sensitivity to fludarabine in CLL cells with lesions in the TP53 pathway; a potential treatment strategy for fludarabine refractory disease. O Giles Best, Yiping Che, Nisha Singh, Cecily Forsyth, Christopherson Richard I, Stephen P Mulligan. Leuk Lymphoma. 2012;53(7):1367-75

  22. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, To LB. Intern Med J 2012;42:450-5.

  23. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Peter J. Campbell, Cathy MacLean, Philip A. Beer, Georgina Buck, Keith Wheatley, Jean-Jacques Kiladjian, Cecily Forsyth, Claire N. Harrison, Anthony R. Green. Blood 2012 Aug 16:120(7):1409-11.

  24. Immunoglobulin G (IgG) subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukaemia. Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson W, Mulligan SP. Leuk Lymphoma. 2013 Jan; 54(1):99-104.

  25. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in pateitns with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Verner E, Forsyth C, Grigg A. Leuk Lymphoma. 2014 May; 55(5): 1139-43

  26. A multicentre, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas. Cecily J Forsyth, David Gomez-Almaguer, Johnny F.C. Camargo, Paul E. Eliadis, Erick Crespo-Solis, Juliana Pereira, Cesar H. Gutierrez-Aguirre, Silvia Rivas-Vera, Stephanie Roberson, Boris Lin, Neil V.Smith, Oday Hamid. Clinical Lymphoma, Myeloma & Leukaemia. 2013 Aug 13 (4): 398-403.

  27. Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Michael J. Paidasa, Cecily Forsyth, Isabelle Quere, Marc Rodger, Johan T.M. Frielinge, R. Campbell Tait. Blood Coagulation and Fibrinolysis. 2014 July 25 (5): 444-450.

  28. The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: Implications for myelodysplasia and aplastic anaemia. Ashish Banerjee, Nicole A. Mifsud, R. Bird, Forsyth, J. Szer, C. Tam, S. Kellner, A. Grigg, P. Motum, M. Bentley, Stephen Opat and George Grigoriadis. Br J Haematol. 2015 Feb 1;168(4):576-82.

  29. TIDEL-II:first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, ISsa S, Hiwase KD, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP. Blood. 2015 Feb 5;125(6):915-23.

  30. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. Douglas G, Harrison C, Forsyth C, Bennett M, Stevenson W, Hounsell J, Ratnasingam S, Ritchie D, Ross DM, Grigg A. Leuk Lymphoma. 2016 Jul 25:1-7

  31. Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms. Malherbe JA, Fuller KA, Mirzai B, Kavanagh S, So CC, Ip HW, Guo BB, Forsyth C, Howman R, Erber WN. J Clin Pathol. 2016; 0:1-8

  32. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: Final analysis of the phase II RevLite study. Hang Quach, Liam Fernyhough, Ross Henderson, Gillian Corbett, Bart Baker, Peter Browett, Hilary Blacklock, Cecily Forsyth, Craig Underhill, Paul Cannell, Judith Trotman, Annette Neylon, Simon Harrison, Emma Link, Arlene Swern, Linda Cowan, Meletios A. Dimopoulos, H. Miles Prince. Br J Haematol. 2017 Feb 177:441-448.

  33. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. Ho J, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins A, Ross D. Intern Med J. 2017 Mar; 47(3):262-268.

  34. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape:data form targeted next-generation sequencing in the diagnosistic laboratory. Rishu Agarwal, Piers Blombery, Michelle McBean, Kate Jones, Andrew Fellowes, Ken Doig, Cecily Forsyth, David Westerman. Ann Hematol. 2017 May; 96(5):725-732.

  35. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukaemia. Lucy C. Fox, Catherine D. Cummins, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Sean Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Fay Putt and Andrew Grigg. Blood Advances 2017 1:802-811

  36. Racoon eyes in systemic AL-amyloidosis. Forsyth Cecily, Tiley Campbell. Med J Aust. 2017 May 15;206(9):384

  37. Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses. Shalini Balendran, Alexander Harrison, Marie-Christine Morel-Kopp, Christopher Ward, Cecily Forsyth. Int Med J. 2018 Jan; 48:98-100

  38. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. Br J Haem Kyle R. Crassini, Eva Zhang, Shalini Balendran, Jane A. Freeman, O. Giles Best1, Cecily J. Forsyth, Naomi J. Mackinlay, Ping Han, William S. Stevenson and Stephen P. Mulligan. Br J Haematol 2018;181(1):97-101

  39. The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications. Cecily Forsyth, Kate Melville, Campbell Tiley. Pathology. 2018;50(7):775-776.

  40. Hydroxycarbamide plus aspirin vs aspirin alone in patients with essential thrombocythaemia aged 40-59 years without high-risk features. Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, McMullin MF, Forsyth C, Kiladjian JJ, Green AR, Harrison CN. J Clin Oncol. 2018;36(34):3361-3369.

  41. Hereditary haemorrhagic telangiectasia. Varitsara Mangkorntongsakul, Cecily Forsyth. Med J Aust. 2019; 210(1):16.

  42. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms. Cecily J. Forsyth, Wai-Hoong Chan, Andrew P. Grigg, Nathalie C Cook, Steven W. Lane, Kate L. Burbury, Andrew C. Perkins, and David M. Ross. Int Med J. 2019;49(8):948-954.

  43. Changing incidence of myeloproliferative neoplasms in Australia, 2003‐ Peter D. Baade, David M. Ross,  Lesley A. Anderson,  Cecily Forsyth,  Lin Fritschi. American Journal of Haematology. 2019; 94(4):E107-109.

  44. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. Adrian G. Minson, Katherine Cummins, Lucy Fox, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, and Andrew Grigg. Blood Advances. 2019; 3(7):1084-1091.

  45. Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation. Maansi Joshi, John Taper, Cecily Forsyth, Philip Rowlings, Philip Campbell, Philip Crispin, Michael Harvey, Craig Underhill, Angela Bayley, Karen Byth, Gillian Huang, Mark Hertzberg. Leukaemia and 2020;61(1):91-97.

  46. RUNX1 mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Anna Brown, Peer Arts, Catherine Carmichael, Milena Babic, Julia Dobbins, Chan-Eng Chong, Andreas Schreiber, Jinghua Feng, Kerry Phillips, Paul Wang, Thuong Ha, Claire Homan, Sarah King-Smith, Lesley Rawlings, Cassandra Valkulin, Andrew Dubowsky, Jessica Burdett, Sarah Moore, Grace McKavanagh, Denae Henry, Amanda Wells, Belinda Mercorella, Mario Nicola, Jeffrey Suttle, Ella Wilkins, Xiao-Chun Li, Joelle Michaud, Peter Brautigan, Ping Cannon, Meryl Altree, Louise Jaensch, Miriam Fine, Carolyn Butcher, Richard D'Andrea, Ian Lewis, Devendra Hiwase, Elli Papaemmanuil, Marshall Horwitz, Georges Natsoulis, Hugh Rienhoff Jr., Nigel Patton, Sally Mapp, Rachel Susman, Susan Morgan, Julian Cooney, Mark Currie, Uday Popat, Tilmann Bochtler, Shai Izraeli, Kenneth Bradstock, Lucy Godley, Alwin Krämer, Stefan Fröhling, Andrew Wei, Cecily Forsyth, Helen Mar Fan, Nicola Poplawski, Christopher Hahn, and Hamish Scott. Blood Advances. 2020;4(6):1131-1144.

  47. Two monogenic disorders masquerading as one:severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing loss. Parvathy Venugopal, Lucia Gagliardi, Cecily Forsyth, Jinghua Feng, Kerry Phillips, Milena Babic, Nicola Poplawski, Hugh Young Rienhoff Jr, Andreas W Schreiber, Christopher N Hahn, Anna L Brown, Hamish Scott. BMC Medical Genetics. 2020;21(1):35.

  48. Cutaneous multiple myeloma. Cecily Forsyth, Sara Lai, Jacqueline Jagger. Br J Haematol 2020;190:134.

  49. Efficacy and safety of ABP 798: Results from the JASMINE trial in patients with follicular lymphoma in comparison with rituximab reference product. Dietger Niederwieser, Caroline Hamm, Patrick Cobb, Mindy Mo, Cecily Forsyth, Alessandra Tucci, Vladimir Hanes, Vincent Delwail, Roman Hajek & David Chien. Targeted Oncology 2020;15:599–611.